<DOC>
	<DOCNO>NCT02730104</DOCNO>
	<brief_summary>The purpose trial ass time disease progression patient locally advance metastatic gastroenteropancreatic neuroendocrine tumor treat Lanreotide Depot . This observational study therefore data collect accordance routine practice physician .</brief_summary>
	<brief_title>Community-based Neuroendocrine Tumor ( NET ) Research Study</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic , welldifferentiated neuroendocrine tumor ( NET ) small bowel , stomach , colon/rectum , pancreas ( low intermediate grade ; i.e . G1 G2 ) Treatment lanreotide depot ( Somatostatin Analoguena√Øve patient patient prior treatment octreotide longacting repeatable ( LAR ) permit ) Radiographically measurable disease Has sign recent write Patient Informed Consent Form Known hypersensitivity lanreotide Poorly differentiate high grade carcinoma , patient neuroendocrine tumor lung thymic origin Patients previously initiate treatment lanreotide depot prior start study progress lanreotide initiation study entry Significant history uncontrolled cardiac disease ( ie , myocardial infarction within 6 month prior enrollment congestive heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>